TD Asset Management
PTGX icon

TD Asset Management’s Protagonist Therapeutics PTGX Stock Holding History

TD Asset Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.5M Sell
134,950
-48,750
-27% -$5.09M 0.01% 546
2026
Q1 		$19.4M Buy
183,700
+24,970
+16% +$2.21M 0.02% 515
2025
Q4 		$13.9M Buy
158,730
+8,302
+6% +$680K 0.01% 582
2025
Q3 		$9.99M Buy
150,428
+34,096
+29% +$1.94M 0.01% 653
2025
Q2 		$6.43M Sell
116,332
-53,600
-32% -$2.57M 0.01% 732
2025
Q1 		$8.22M Sell
169,932
-3,770
-2% -$158K 0.01% 688
2024
Q4 		$6.7M Buy
173,702
+1,500
+0.9% +$65.4K 0.01% 731
2024
Q3 		$7.67M Buy
172,202
+23,900
+16% +$966K 0.01% 693
2024
Q2 		$5.14M Buy
148,302
+39,850
+37% +$1.17M ﹤0.01% 760
2024
Q1 		$3.14M Sell
108,452
-2,348
-2% -$63.9K ﹤0.01% 892
2023
Q4 		$2.54M Hold
110,800
– – ﹤0.01% 929
2023
Q3 		$1.85M Buy
110,800
+55,400
+100% +$1.07M ﹤0.01% 979
2023
Q2 		$1.53M Buy
55,400
+26,400
+91% +$661K ﹤0.01% 1026
2023
Q1 		$667K Buy
+29,000
New +$487K ﹤0.01% 1215
2022
Q2 		– Sell
-17,842
Closed -$422K – 1505
2022
Q1 		$422K Sell
17,842
-15,200
-46% -$428K ﹤0.01% 1358
2021
Q4 		$1.13M Sell
33,042
-14,000
-30% -$443K ﹤0.01% 1256
2021
Q3 		$834K Sell
47,042
-21,800
-32% -$929K ﹤0.01% 1298
2021
Q2 		$3.4M Buy
68,842
+7,371
+12% +$243K ﹤0.01% 932
2021
Q1 		$1.59M Buy
61,471
+10,219
+20% +$259K ﹤0.01% 1158
2020
Q4 		$1.03M Buy
51,252
+11,899
+30% +$256K ﹤0.01% 1178
2020
Q3 		$769K Hold
39,353
– – ﹤0.01% 1138
2020
Q2 		$695K Buy
+39,353
New +$494K ﹤0.01% 1147

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

TD Asset Management's PTGX Position: Q2 2026 in Review

TD Asset Management reduced its Protagonist Therapeutics (PTGX) stake by 27% in Q2 2026, selling an estimated $5.09M and leaving 134,950 shares worth $16.5M. The position accounts for 0.01% of the portfolio, ranked #546.

TD Asset Management first reported a position in PTGX in Q2 2020 and has held it in 22 quarters since. The position peaked at $19.4M in Q1 2026. 244 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • TD Asset Management held 134,950 shares of Protagonist Therapeutics worth $16.5M as of Q2 2026.
  • TD Asset Management sold 48,750 Protagonist Therapeutics shares in Q2 2026, an estimated $5.09M.
  • Protagonist Therapeutics made up 0.01% of TD Asset Management's portfolio in Q2 2026, its #546 holding.
  • TD Asset Management first reported a position in Protagonist Therapeutics in Q2 2020 and has held it in 22 quarters since.
  • TD Asset Management's Protagonist Therapeutics position peaked at $19.4M in Q1 2026.
  • 244 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on TD Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.